Business
EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors
WATERTOWN, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and
About this update from Eyepoint, Inc.
[{"type":"text","content":"WATERTOWN, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the election of Anthony (Tony) Adamis, M.D. to its Board of Directors. Dr. Adamis is a highly accomplished ophthalmology executive with more than 30 years of research and development experience in the biopharmaceutical industry. “Dr. Adamis is a pioneer in the discovery and early development of anti-VEGF drugs for the treatment of ophthalmic diseases and will be an invaluable member of our Board of Directors,” said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. “Tony brings a stellar track record of guiding the development of 20 medicines and 25 approvals by the U.S. Food and Drug Administration, and we look forward to leveraging his expertise as we continue to build our company and progress our lead pipeline asset, EYP-1901, through the clinic for multiple ophthalmic indications.” “It is my pleasure to welcome Dr. Adamis to EyePoint’s Board of Directors,” said Dr. Göran Ando, M.D., Chair of the Board of EyePoint Pharmaceuticals. “Tony’s scientific and operational experience developing innovative ocular therapies from early discovery to commercial stages uniquely position him to provide valuable input as we work as we work towards EyePoint’s goal of becoming the leader in ocular drug delivery technology. On behalf of the Board of Directors, we are excited to have Tony’s expertise and look forward to collaborating with him.” Dr. Adamis is best-known for his co-discovery of the role of vascular endothelial growth factor (VEGF) in ocular disease, including wet age-related macular degeneration (AMD) and diabetic retinopathy. Prior to joining the EyePoint Board of Directors, Dr. Adamis served in various roles at Genentech/Roche, most recently as Senior Vice President, Development Innovation, and spearheaded the first FDA-approved drugs for diabetic macular edema and diabetic retinopathy, among several others. Previously, he was a co-founder, director, president, and CEO of Jerini Ophthalmic. Dr. Adamis also co-founded EyeTech Pharmaceuticals, which obtained FDA approval for the first anti-VEGF drug in ophthalmology, and was acquired by OSI Pharmaceuticals in 20...